ALB and acute myeloid leukemia: A large-scale, multicenter clinical study (Sun et al., 2015) found that risk factors of IFD among chemotherapy patients with malignant hematologic disease included neutropenia, AML or MDS, non-CR patients who receipt of induction chemotherapy or repeat induction chemotherapy, decreased serum albumin levels, and CVC.